Venture Capital

Everest Medicines Completes Us$310 Million Series C Financing

by posted 1year ago 57 views
SHANGHAI, China, June 4, 2020-- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that it has successfully completed US$310 million in Series C financing. The US$310 million Series C financing includes two preferred equity financing tranches, a US$260 million Series C-2 and a US$50 million Series C-1.